Barclays recorded Charles River (NYSE:CRL), upping its target price to $77.00 earlier today
- Updated: November 30, 2016
Barclays increased the stock price target of Charles River (NYSE:CRL) to $77.00 indicating a possible upside of 0.08%.
On 2/11/2016, UBS Securities released a statement about Charles River (NYSE:CRL) bumped up the target price from $75.00 to $76.00 that suggested an upside of 0.07%.
Showing a price of $71.56, Charles River (NYSE:CRL) traded 2.07% higher on the day. The last stock price is down -10.75% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same period. CRL has recorded a 50-day average of $76.01 and a two hundred day average of $81.84. Trade Volume was down over the average, with 11,698 shares of CRL changing hands under the typical 460,870
See Chart Below
Charles River has a 52 week low of $65.70 and a 52 week high of $89.18 with a price-earnings ratio of 24.68 CRL’s total market value is presently $0.
A total of 15 equity analysts have released a ratings update on CRL. Six analysts rating the company a strong buy, 3 firms rating the stock a buy, 8 brokerages rating the company a hold, two brokerages rating the company a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $85.47.
More About Charles River (NYSE:CRL)
Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.